Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K

Navidea Biopharmaceuticals reports 2019 executive compensation

By ExecPay News

Published: July 31, 2020

Navidea Biopharmaceuticals reported fiscal year 2019 executive compensation information on July 31, 2020.
In 2019, two executives at Navidea Biopharmaceuticals received on average a compensation package of $495K, a 17% decrease compared to previous year.
Average pay of disclosed executives at Navidea Biopharmaceuticals
Jed A. Latkin, Chief Executive Officer, received $740K in total, which increased by 16% compared to 2018. 64% of Latkin's compensation, or $475K, was in salary. Latkin also received $178K in non-equity incentive plan, $81K in option awards, as well as $5.6K in other compensation.
Michael S. Rosol, Chief Medical Officer, received a compensation package of $250K, which increased by 2077% compared to previous year. 82% of the compensation package, or $205K, was in salary.

Related executives

Jed Latkin

Navidea Biopharmaceuticals

Chief Executive Officer

Michael Rosol

Navidea Biopharmaceuticals

Chief Medical Officer

You may also like

Source: SEC filing on July 31, 2020.